19.565 USD
+2.48 (+14.48%)
ChartMill assigns a Buy % Consensus number of 86% to IMNM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.48. This target is 25.12% above the current price.
IMNM was analyzed by 18 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about IMNM.
In the previous month the buy percentage consensus was at a similar level.
IMNM was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-01 | Truist Securities | Initiate | Buy |
| 2025-11-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-09-22 | Goldman Sachs | Initiate | Buy |
| 2025-09-05 | Craig-Hallum | Initiate | Buy |
| 2025-08-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-08-22 | Evercore ISI Group | Initiate | Outperform |
| 2025-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-02 | Lake Street | Initiate | Buy |
| 2025-03-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-11 | LifeSci Capital | Initiate | Outperform |
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-04-30 | JP Morgan | Initiate | Overweight |
| 2024-04-15 | Guggenheim | Initiate | Buy |
| 2024-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-19 | Wedbush | Initiate | Outperform |
| 2023-03-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-03-17 | Chardan Capital | Maintains | Buy |
| 2021-10-29 | Cantor Fitzgerald | Initiate | Overweight |
IMMUNOME INC / IMNM FAQ
What is the average price target for IMMUNOME INC (IMNM) stock?
18 analysts have analysed IMNM and the average price target is 24.48 USD. This implies a price increase of 25.12% is expected in the next year compared to the current price of 19.565.
How do analysts rate IMMUNOME INC (IMNM)?
The consensus rating for IMMUNOME INC (IMNM) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.